Clinical trials
Adebrelimab clinical trials
Below are recruiting adebrelimab clinical trials, each written for real people, not researchers. We’re tracking 131 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06913777RecruitingPhase 3
Precision therapy before surgery for HR-positive breast cancer
This trial tests a new precision therapy given before surgery for women with a specific type of HR-positive breast cancer. It aims to see if this treatment can improve outcomes.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06943235RecruitingPhase 2
Probiotics, radiation, chemo, and immunotherapy for limited-stage small cell lung cancer
This trial tests if adding probiotics (good bacteria) to standard chemoradiation and an immunotherapy drug (adebrelimab) can help treat limited-stage small cell lung cancer. It may improve how well the treatment works and reduce side effects.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06908668RecruitingPhase 2
Adebrelimab plus chemo with or without radiation before breast cancer surgery
This trial tests adding a drug called adebrelimab to standard chemotherapy and possibly radiation, given before surgery for breast cancer that is HER2-negative and locally advanced. The goal is to see if this combination helps shrink tumors more effectively, potentially allowing for breast-conserving surgery.
BeijingAges 18–70 - NCT06902792Enrolling by invitationPhase 1
Adebrelimab and trametinib for children with hard-to-treat LCH
This trial tests a combination of two drugs for children and teens with Langerhans cell histiocytosis (LCH) that has not responded to standard treatments or has come back after treatment. The goal is to see if the drugs can shrink lesions and improve symptoms.
Wenzhou, ZhejiangAges Up to 18 years - NCT06893887Recruiting
Personalized treatment for advanced liver cancer
This trial tests a personalized treatment plan for people whose advanced liver cancer (hepatocellular carcinoma) has progressed after initial targeted and immune therapy. It aims to find a next-step option tailored to your specific situation.
Nanjing, JiangsuAges 18 years+ - NCT06840002RecruitingPhase 1/Phase 2
Targeted drug plus chemotherapy for recurrent ovarian cancer
This trial tests a new targeted drug, SHR-A1811, combined with chemotherapy for women whose ovarian cancer has returned but still responds to platinum-based drugs. The goal is to see if the combination works better than chemotherapy alone.
Wuhan, HubeiAges 18–75 - NCT06844474RecruitingPhase 2
Study of SHR-1826 for advanced lung cancer
This trial tests an investigational drug called SHR-1826 for people with non-small cell lung cancer that has spread or cannot be removed by surgery. It aims to see if the drug can shrink tumors and improve outcomes.
Beijing, Beijing MunicipalityAges 18–75 - NCT06703177RecruitingPhase 1/Phase 2
Study of SHR-1826 combo for advanced solid tumors
This trial tests a new drug, SHR-1826, combined with other cancer treatments for people with advanced solid tumors that have not responded to prior therapy. The goal is to see if the combination is safe and effective.
Guangzhou, GuangdongAges 18–75 - NCT06547736RecruitingPhase 2
Precision treatment for advanced pancreatic cancer
This trial tests personalized therapies for people with advanced pancreatic cancer that has spread or cannot be removed. It aims to find the best treatment based on your tumor's unique features.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06452602RecruitingPhase 2
Chemo-immunotherapy before chemoradiation for esophageal cancer
This trial tests giving chemotherapy plus immunotherapy first, followed by standard chemoradiation, for people with advanced esophageal cancer that cannot be surgically removed. It aims to see if this approach improves outcomes.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06417554RecruitingPhase 1/Phase 2
Study of SHR-A2102 for advanced solid tumors
This trial is testing a new drug, SHR-A2102, either alone or with other treatments, for people with advanced solid tumors that have stopped responding to standard therapy. The goal is to see if it can shrink tumors or slow the cancer's growth.
Beijing, Beijing MunicipalityAges 18–80
Hear when a new Adebrelimab trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for adebrelimab?
- Yes. Clin2 currently lists 131 recruiting adebrelimab studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a adebrelimab trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a adebrelimab trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.